Ali Bidari1, Ehsan Moazen-Zadeh2,3, Banafsheh Ghavidel-Parsa4, Shahrzad Rahmani1, Sajjad Hosseini5, Amir Hassankhani5. 1. Department of Rheumatology, Iran University of Medical Sciences, Tehran, Iran. 2. Psychiatric Research Center, Roozbeh Hospital, Tehran University of Medical Sciences, Tehran, Iran. 3. Institute of Mental Health, Department of Psychiatry, University of British Columbia, Vancouver, Canada. 4. Rheumatology Research Center, Razi Hospital, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran. bghavidelparsa@gmail.com. 5. Department of General Medicine, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran.
Abstract
BACKGROUND:Duloxetine and pregabalin are among the most widely used medications in the treatment of patients with fibromyalgia syndrome (FM). OBJECTIVES: To add to the very few lines of evidence that exist on the comparative safety and efficacy of these two medications. METHODS: In this open-label randomized clinical trial, outpatient women, who were diagnosed with FM based on American College of Rheumatology 2010 criteria, and had an age range of 18-65 years old were assigned to either duloxetine 30-60 mg or pregabalin 75-150 mg per day for 4 weeks. Patients were excluded in cases of having used duloxetine, pregabalin, gabapentin, or antidepressantswithin 12 weeks prior to the study, having had a history of comorbid medical conditions that could provoke chronic pain, or having had comorbid neuropsychiatric disorders, except for major depressive/anxiety disorders. Primary outcomes were between-group differences in mean score changes from baseline to end point for Widespread Pain Index (WPI) and Beck Depression Inventory-II. Secondary outcomes were the same statistical estimates, but for Fibromyalgia Impact Questionnaire-Revised and 12-Item Short Form Survey. Descriptive statistics and independent samples t-test were the main methods of analysis. ( www.irct.ir ; IRCT2016030626935N1). RESULTS: Among all the scales, only WPI scores improved with a statistically significant difference between the two treatment arms, favoring duloxetine (Mean difference in score change - 2.32, 95% CI, -4.46 to - 0.18; p = 0.034; Cohen's d 0.53 95% CI, 0.04 to 1.02). Drop out rate and cumulative incidence of nausea was significantly higher in the duloxetine arm compared to the pregabalin arm. CONCLUSION: This study provides further evidence on higher efficacy of duloxetine compared to pregabalin for the treatment of pain in patients with fibromyalgia. Future comprehensive pragmatic clinical trials are warranted.
RCT Entities:
BACKGROUND:Duloxetine and pregabalin are among the most widely used medications in the treatment of patients with fibromyalgia syndrome (FM). OBJECTIVES: To add to the very few lines of evidence that exist on the comparative safety and efficacy of these two medications. METHODS: In this open-label randomized clinical trial, outpatientwomen, who were diagnosed with FM based on American College of Rheumatology 2010 criteria, and had an age range of 18-65 years old were assigned to either duloxetine 30-60 mg or pregabalin 75-150 mg per day for 4 weeks. Patients were excluded in cases of having used duloxetine, pregabalin, gabapentin, or antidepressants within 12 weeks prior to the study, having had a history of comorbid medical conditions that could provoke chronic pain, or having had comorbid neuropsychiatric disorders, except for major depressive/anxiety disorders. Primary outcomes were between-group differences in mean score changes from baseline to end point for Widespread Pain Index (WPI) and Beck Depression Inventory-II. Secondary outcomes were the same statistical estimates, but for Fibromyalgia Impact Questionnaire-Revised and 12-Item Short Form Survey. Descriptive statistics and independent samples t-test were the main methods of analysis. ( www.irct.ir ; IRCT2016030626935N1). RESULTS: Among all the scales, only WPI scores improved with a statistically significant difference between the two treatment arms, favoring duloxetine (Mean difference in score change - 2.32, 95% CI, -4.46 to - 0.18; p = 0.034; Cohen's d 0.53 95% CI, 0.04 to 1.02). Drop out rate and cumulative incidence of nausea was significantly higher in the duloxetine arm compared to the pregabalin arm. CONCLUSION: This study provides further evidence on higher efficacy of duloxetine compared to pregabalin for the treatment of pain in patients with fibromyalgia. Future comprehensive pragmatic clinical trials are warranted.
Authors: Chi-Un Pae; Patrick Luyten; David M Marks; Changsu Han; Sung-Hwan Park; Ashwin A Patkar; Prakash S Masand; Boudewijn Van Houdenhove Journal: Curr Med Res Opin Date: 2008-07-04 Impact factor: 2.580
Authors: Mario D Cordero; Manuel de Miguel; Inés Carmona-López; Pablo Bonal; Francisco Campa; Ana María Moreno-Fernández Journal: Neuro Endocrinol Lett Date: 2010 Impact factor: 0.765
Authors: Frederick Wolfe; Daniel J Clauw; Mary-Ann Fitzcharles; Don L Goldenberg; Robert S Katz; Philip Mease; Anthony S Russell; I Jon Russell; John B Winfield; Muhammad B Yunus Journal: Arthritis Care Res (Hoboken) Date: 2010-05 Impact factor: 4.794
Authors: Robert M Bennett; Ronald Friend; Kim D Jones; Rachel Ward; Bobby K Han; Rebecca L Ross Journal: Arthritis Res Ther Date: 2009-08-10 Impact factor: 5.156
Authors: Hannah W Haddad; Allison C Jumonville; Katarina J Stark; Shavonne N Temple; Chukwudum C Dike; Elyse M Cornett; Alan D Kaye Journal: Health Psychol Res Date: 2021-06-28
Authors: Mark D Namba; Jonna M Leyrer-Jackson; Erin K Nagy; M Foster Olive; Janet L Neisewander Journal: Front Neurosci Date: 2021-04-15 Impact factor: 4.677
Authors: Bala Munipalli; Madeleine E Allman; Mohit Chauhan; Shehzad K Niazi; Fernando Rivera; Andy Abril; Benjamin Wang; Mikolaj A Wieczorek; David O Hodge; Dacre Knight; Adam Perlman; Abd Moain Abu Dabrh; Daniel Dudenkov; Barbara K Bruce Journal: J Prim Care Community Health Date: 2022 Jan-Dec